ATE326225T1 - Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms - Google Patents

Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms

Info

Publication number
ATE326225T1
ATE326225T1 AT02721191T AT02721191T ATE326225T1 AT E326225 T1 ATE326225 T1 AT E326225T1 AT 02721191 T AT02721191 T AT 02721191T AT 02721191 T AT02721191 T AT 02721191T AT E326225 T1 ATE326225 T1 AT E326225T1
Authority
AT
Austria
Prior art keywords
treatment
bowel syndrome
irgitable
xanthine
glycol derivatives
Prior art date
Application number
AT02721191T
Other languages
German (de)
English (en)
Inventor
Brian E Huber
Allen Wayne Mangel
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE326225T1 publication Critical patent/ATE326225T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02721191T 2001-02-28 2002-02-26 Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms ATE326225T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27211501P 2001-02-28 2001-02-28

Publications (1)

Publication Number Publication Date
ATE326225T1 true ATE326225T1 (de) 2006-06-15

Family

ID=23038466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721191T ATE326225T1 (de) 2001-02-28 2002-02-26 Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms

Country Status (7)

Country Link
EP (1) EP1372661B1 (enExample)
JP (1) JP2004523559A (enExample)
AT (1) ATE326225T1 (enExample)
AU (1) AU2002252134A1 (enExample)
DE (1) DE60211495T2 (enExample)
ES (1) ES2262798T3 (enExample)
WO (1) WO2002067942A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN101027303A (zh) 2004-07-27 2007-08-29 吉里德科学公司 咪唑并[4，5－d]嘧啶类、其应用和制备方法
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017577A (en) * 1986-04-25 1991-05-21 Burroughs Wellcome Co. Methods for treating viral infection
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
WO1999043673A1 (en) * 1998-02-26 1999-09-02 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2002067942A2 (en) 2002-09-06
DE60211495D1 (de) 2006-06-22
ES2262798T3 (es) 2006-12-01
WO2002067942A3 (en) 2003-02-06
EP1372661B1 (en) 2006-05-17
AU2002252134A1 (en) 2002-09-12
EP1372661A2 (en) 2004-01-02
JP2004523559A (ja) 2004-08-05
DE60211495T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
TR200302309T4 (tr) Fosfodiesterazın yararlı inhibitörleri olarak beta-karbolin türevleri.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
DE60330485D1 (de) Zur behandlung von diabetes
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE463492T1 (de) Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
NO20052690L (no) Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke.
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE326225T1 (de) Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms
CY1106409T1 (el) Παραγωγα κινολινης
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
SE0302304D0 (sv) Novel compounds
ATE476982T1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties